CR20130027A - COMBINACIÓN DEL COMPUESTO GlyT1 CON ANTIPSICÓTICOS - Google Patents

COMBINACIÓN DEL COMPUESTO GlyT1 CON ANTIPSICÓTICOS

Info

Publication number
CR20130027A
CR20130027A CR20130027A CR20130027A CR20130027A CR 20130027 A CR20130027 A CR 20130027A CR 20130027 A CR20130027 A CR 20130027A CR 20130027 A CR20130027 A CR 20130027A CR 20130027 A CR20130027 A CR 20130027A
Authority
CR
Costa Rica
Prior art keywords
glyt1
combination
antipsychotics
compound
schizophrenia
Prior art date
Application number
CR20130027A
Other languages
English (en)
Inventor
Daniela Alberati
Jean-Luc Moreau
Joseph G Wettstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130027(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20130027A publication Critical patent/CR20130027A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica de un inhibidor del transportador de glicina (GlyT1) y un fármaco antipsicótico atípico que puede utilizarse para el tratamiento de los síntomas positivos y negativos de la esquizofrenia.
CR20130027A 2010-08-09 2013-01-22 COMBINACIÓN DEL COMPUESTO GlyT1 CON ANTIPSICÓTICOS CR20130027A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09

Publications (1)

Publication Number Publication Date
CR20130027A true CR20130027A (es) 2013-03-04

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130027A CR20130027A (es) 2010-08-09 2013-01-22 COMBINACIÓN DEL COMPUESTO GlyT1 CON ANTIPSICÓTICOS

Country Status (28)

Country Link
US (1) US20120035156A1 (es)
EP (1) EP2603219B1 (es)
JP (1) JP2013533297A (es)
KR (1) KR101455947B1 (es)
CN (1) CN103068388A (es)
AR (1) AR084401A1 (es)
AU (1) AU2011288536B2 (es)
BR (1) BR112013003068A2 (es)
CA (1) CA2803656A1 (es)
CL (1) CL2013000378A1 (es)
CR (1) CR20130027A (es)
CY (1) CY1115886T1 (es)
DK (1) DK2603219T3 (es)
EA (1) EA201291477A1 (es)
EC (1) ECSP13012431A (es)
ES (1) ES2521596T3 (es)
HR (1) HRP20141199T1 (es)
MA (1) MA34457B1 (es)
MX (1) MX2013001166A (es)
NZ (1) NZ604891A (es)
PE (1) PE20131100A1 (es)
PL (1) PL2603219T3 (es)
PT (1) PT2603219E (es)
SG (1) SG187108A1 (es)
SI (1) SI2603219T1 (es)
TW (1) TW201211019A (es)
WO (1) WO2012019970A1 (es)
ZA (1) ZA201300434B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158903A1 (en) 2011-09-08 2015-06-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT3461834T (pt) 2013-03-13 2021-09-10 Sage Therapeutics Inc Esteroides neuroativos
AR098572A1 (es) * 2013-12-03 2016-06-01 Hoffmann La Roche Composición farmaceutica
KR20160147868A (ko) * 2014-04-30 2016-12-23 위펑 제인 쳉 D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
US20170304321A1 (en) * 2014-10-07 2017-10-26 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
CN108135911B (zh) 2015-07-06 2021-06-25 萨奇治疗股份有限公司 氧甾醇及其使用方法
SG10202010553XA (en) 2015-07-06 2020-12-30 Sage Therapeutics Inc Oxysterols and methods of use thereof
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (pl) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
JP2019532079A (ja) 2016-10-18 2019-11-07 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
US11149054B2 (en) 2016-10-18 2021-10-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CA3081226A1 (en) * 2017-11-14 2019-05-23 Sk Biopharmaceuticals Co., Ltd. Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
WO2021142329A1 (en) 2020-01-09 2021-07-15 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009986B1 (ru) 2003-08-11 2008-04-28 Ф. Хоффманн-Ля Рош Аг Пиперазин с or-замещенной фенильной группой и его применение в качестве ингибиторов glyt1
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
ES2520015T3 (es) * 2005-04-08 2014-11-11 Pfizer Products Inc. [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
UA94615C2 (uk) * 2006-06-28 2011-05-25 Амген Інк. Інгібітори транспортера-1 гліцину

Also Published As

Publication number Publication date
ES2521596T3 (es) 2014-11-13
MA34457B1 (fr) 2013-08-01
PT2603219E (pt) 2014-11-25
CA2803656A1 (en) 2012-02-16
ECSP13012431A (es) 2013-03-28
KR20130045379A (ko) 2013-05-03
EP2603219A1 (en) 2013-06-19
EA201291477A1 (ru) 2013-06-28
BR112013003068A2 (pt) 2016-06-28
ZA201300434B (en) 2013-09-25
JP2013533297A (ja) 2013-08-22
CN103068388A (zh) 2013-04-24
AR084401A1 (es) 2013-05-15
EP2603219B1 (en) 2014-09-17
KR101455947B1 (ko) 2014-10-28
AU2011288536A1 (en) 2013-01-31
TW201211019A (en) 2012-03-16
PE20131100A1 (es) 2013-09-23
NZ604891A (en) 2015-01-30
PL2603219T3 (pl) 2015-03-31
DK2603219T3 (da) 2014-10-13
SI2603219T1 (sl) 2014-12-31
MX2013001166A (es) 2013-03-22
CL2013000378A1 (es) 2013-05-03
CY1115886T1 (el) 2017-01-25
US20120035156A1 (en) 2012-02-09
SG187108A1 (en) 2013-02-28
WO2012019970A1 (en) 2012-02-16
AU2011288536B2 (en) 2014-10-09
HRP20141199T1 (hr) 2015-02-13

Similar Documents

Publication Publication Date Title
ECSP13012431A (es) Combinación del compuesto glyt1 con antipsicóticos
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
GT201200144A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina
CR20130616A (es) Amidas-2-piridina útiles como agonistas cb2
CR20150447A (es) Nuevos derivados de pirazol
GT201200230A (es) Inhibidores del virus de la hepatitis c
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
EA201590807A1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
ECSP13012414A (es) Combinaciones que comprenden antipsicóticos atípicos y agonistas taar1
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
CR20150511A (es) Nuevos derivados de purina
CR20150440A (es) Nuevos derivados de piridina
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
BR112013027403A2 (pt) composições que compreendem uma antimetabólito de glicose e selênio
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
CR20150275A (es) Composición de difenidol de liberación prolongada
BR112014019220A8 (pt) Novos derivados de pirrolidina
CU20150173A7 (es) COMPOSICIÓN FARMACÉUTICA QUE INCLUYE UN INHIBIDOR DE LA HMG-Coa REDUCTASA QUE MINIMIZA LA INTERACCIÓN DEL ÁCIDO ÁCIDO ACETILSALICÍLICO CON LA ESTATINA
SV2015004997A (es) Comprimidos que tienen aceptacion mejorada y buena estabilidad durante el almacenamiento